Key result
Apixaban and rivaroxaban showed no significant differences in 180-day risks of all-cause mortality, recurrent VTE, or hospitalized bleeding in patients with VTE.
Why the study?
Does apixaban compared to rivaroxaban reduce mortality, recurrent VTE, or bleeding in patients with venous thromboembolism?
Cohort (n=8,187)
Yes
Does apixaban compared to rivaroxaban reduce mortality, recurrent VTE, or bleeding in patients with venous thromboembolism?
In a nationwide cohort of VTE patients, apixaban and rivaroxaban showed similar safety and effectiveness profiles at 180 days.
Answers are grounded in this paper and cite their sources.
Comparable VTE outcomes observed with apixaban and rivaroxaban; leaves open confirmation by randomized trials.
Aims: To investigate the risk of all-cause mortality, recurrent venous thromboembolism (VTE), and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban. Methods and results: Using Danish nationwide registries, patients with VTE treated with rivaroxaban or apixaban in the period from 1 January 2015 to 30 June 2017 were identified. Standardized absolute risks were estimated based on outcome-specific Cox regression models, adjusted for potential confounders. A total of 8187 patients were included in the study, of which 1504 (18%) were treated with apixaban [50% males, median age 70 years; interquartile range (IQR) 56-80] and 6683 (82%) were treated with rivaroxaban (55% males, median age 67 years; IQR 53-76). The 180 days risk of all-cause mortality was 5.08% [95% confidence interval (95% CI) 4.08% to 6.08%)] in the apixaban group and 4.60% (95% CI 4.13% to 5.18%) in the rivaroxaban group [absolute risk difference: -0.48% (95% CI -1.49% to 0.72%)]. The 180 days risk of recurrent VTE was 2.16% (95% CI 1.49% to 2.88%) in the apixaban group and 2.22% (95% CI 1.89% to 2.52%) in the rivaroxaban group [absolute risk difference of 0.06% (95% CI -0.72% to 0.79%)]. The 180 days risk of hospitalized bleeding was 1.73% (95% CI 1.22% to 2.35%) for patients in the apixaban group and 1.89% (95% CI 1.56% to 2.20%) in the rivaroxaban group [absolute risk difference: 0.16% (95% CI -0.59% to 0.81%)]. Conclusion: In a nationwide cohort of 8187 patients with VTE treated with rivaroxaban or apixaban, there were no significant differences in the risks of all-cause mortality, recurrent VTE, or hospitalized bleeding.
No takes yet. Share an insight, caveat, or question.
Sindet‐Pedersen et al. (2018) conducted a cohort in venous thromboembolism (n=8,187). Apixaban vs. Rivaroxaban was evaluated on all-cause mortality (absolute risk difference -0.48%, 95% CI -1.49 to 0.72). Apixaban and rivaroxaban showed no significant differences in 180-day risks of all-cause mortality, recurrent VTE, or hospitalized bleeding in patients with VTE.
Synapse has enriched 10 related papers. Consider them for comparative context: